Keywords: Cell Therapeutics, Puxuvri, FDA, Non-Hodgkin's lympoma, Pixantrone

US FDA calls for more info on Cell Thera’s pixantrone NDA, and firm says it will file for expanded access for NHL patients

Article | 09 April 2010

Print This

Seattle, USA-based Cell Therapeutics revealed this morning that it had received a Complete Response Letter from the Food and Drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in